|
||
© The Rockefeller University Press,
0021-9525/2001/7/447 $5.00
The Journal of Cell Biology, Volume 154, Number 2, July 23, 2001 447-458
Article |
Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin
8ß1 in the embryonic kidney
Address correspondence to Louis F. Reichardt, University of California, San Francisco, School of Medicine, 533 Parnassus Ave., San Francisco, CA 94143-0723. Tel.: (415) 476-3976. Fax: (415) 566-4969. E-mail: lfr{at}cgl.ucsf.edu
| Abstract |
|---|
|
|
|---|
The epithelialmesenchymal interactions required for kidney organogenesis are disrupted in mice lacking the integrin
8ß1. None of this integrin's known ligands, however, appears to account for this phenotype. To identify a more relevant ligand, a soluble integrin
8ß1 heterodimer fused to alkaline phosphatase (AP) has been used to probe blots and cDNA libraries. In newborn mouse kidney extracts,
8ß1-AP detects a novel ligand of 7090 kD. This protein, named nephronectin, is an extracellular matrix protein with five EGF-like repeats, a mucin region containing a RGD sequence, and a COOH-terminal MAM domain. Integrin
8ß1 and several additional RGD-binding integrins bind nephronectin. Nephronectin mRNA is expressed in the ureteric bud epithelium, whereas
8ß1 is expressed in the metanephric mesenchyme. Nephronectin is localized in the extracellular matrix in the same distribution as the ligand detected by
8ß1-AP and forms a complex with
8ß1 in vivo. Thus, these results strongly suggest that nephronectin is a relevant ligand mediating
8ß1 function in the kidney. Nephronectin is expressed at numerous sites outside the kidney, so it may also have wider roles in development. The approaches used here should be generally useful for characterizing the interactions of novel extracellular matrix proteins identified through genomic sequencing projects.
Key Words: integrin; nephronectin; extracellular matrix; organogenesis; kidney
| Introduction |
|---|
|
|
|---|
8ß1 has recently been shown to play a crucial role during early steps of kidney morphogenesis (Müller et al., 1997). This integrin is expressed in the metanephric mesenchyme, but not in the ureteric bud, and is downregulated as the mesenchymal cells undergo epithelialization. In mice homozygous for a mutation in the
8 gene, initial growth and branching of the ureter are severely impaired. Thus the presence of
8ß1 promotes the development of the ureteric bud in a noncell-autonomous manner. Using a soluble
8ß1 heterodimer fused to alkaline phosphatase (AP),* we identified a potential new ligand that is colocalized with
8ß1 at the interface between the ureter and the surrounding mesenchyme (Müller et al., 1997). Fibronectin (FN), vitronectin (VN), tenascin-C (TN-C), and osteopontin (OPN) are ligands for this integrin (Müller et al., 1995; Schnapp et al., 1995b; Varnum-Finney et al., 1995; Denda et al., 1998b). OPN is expressed at the interface between the ureter and the mesenchyme, and inhibition of OPN function impairs kidney development in organ culture (Rogers et al., 1997), but mice lacking OPN develop normal kidneys (Liaw et al., 1998). Thus, OPN alone cannot be mediating
8ß1 function. TN-C and VN are not expressed in the correct spatiotemporal pattern in the kidney to be essential ligands for this integrin (Aufderheide et al., 1987; Seiffert et al., 1991). Moreover, mice lacking TN-C or VN develop without kidney abnormalities (Saga et al., 1992; Zheng et al., 1995). Mice lacking FN die before the onset of kidney development (George et al., 1993), but FN is not expressed in the same pattern in the embryonic kidney as the ligand detected by
8ß1-AP (Ekblom, 1981; unpublished data). Thus, none of these ligands appears to be a strong candidate to mediate the essential functions of
8ß1 in the developing kidney.
To understand the mechanisms of
8ß1 function, we have sought to identify a ligand that mediates its function during kidney morphogenesis. In blots,
8ß1-AP detects several proteins in embryonic kidney extracts, most prominent of which are protein bands of 7090 kD (Müller et al., 1997). In this paper, we have used
8ß1-AP in an expression cloning strategy to identify novel ligands for this integrin. This strategy has yielded cDNAs encoding a novel extracellular matrix protein. Its distribution indicates that it is an extracellular matrix protein, synthesized by the ureteric bud epithelium that is localized with
8ß1 at the interface between the ureteric bud and the metanephric mesenchyme. Because of its localization in the kidney extracellular matrix, we have named it nephronectin. Nephronectin binds to integrin
8ß1 in an RGD-sensitive fashion and is the 7090-kD protein recognized by
8ß1-AP in protein blots. Nephronectin can be coimmunoprecipitated with
8ß1 from kidney extracts, indicating that this integrin and ligand exist in a complex in the kidney in vivo. Based on these findings, we suggest that nephronectin is a ligand in the kidney that mediates
8ß1 function during development.
| Results |
|---|
|
|
|---|
8ß1
8ß1, we used
8ß1-AP, which consists of a heterodimer of the extracellular domain of
8 and the extracellular domain ß1 fused to AP (Fig. 1
A; Denda et al., 1998a). In previous work, this protein complex has been shown to recognize each of the known ligands for integrin
8ß1 and has been used successfully in histochemistry and protein blots (Fig. 1 B; Müller et al., 1997; Denda et al., 1998a,b). In blots using newborn mouse kidney extracts,
8ß1-AP recognizes a prominent group of proteins with molecular masses between 70 and 90 kD (Fig. 1 B). At least two bands can be distinguished within that range plus additional bands with molecular masses >100 kD (Fig. 1 B). Of the higher molecular mass bands, the 200-kD band is likely to be FN (Müller et al., 1997), whereas the other higher molecular weight bands do not comigrate with any of the known ligands for
8ß1. Among the known ligands for integrin
8ß1, OPN (Denda et al., 1998b) and VN (Müller et al., 1995) are expected to comigrate with the 7090-kD proteins and could be responsible for the signals obtained in
8ß1-AP blots. VN, however, is present in adult heart extracts (Fig. 1 D), but the 7090-kD bands do not show up in a blot using this tissue (Fig. 1 C). In contrast, embryonic day 13 heart extract does not contain any detectable VN (Fig. 1 D). Nonetheless,
8ß1-AP recognizes a 7090-kD ligand in a far Western blot of this extract (Fig. 1 C). Similarly, kidney extracts from mice lacking OPN show unchanged levels of the bands between 70 and 90 kD in blots (not shown). Thus, the protein bands at 7090-kD and at least some of the higher molecular weight bands appear to contain additional ligands for integrin
8ß1.
|
8ß1, using
8ß1-AP (Fig. 1 C). Western blots of those expressing such ligands were used to test for the presence of the FN and VN, known
8ß1 ligands with molecular masses in the 7090-kD range. All the tissues tested contained FN (data not shown), but embryonic day 13 (E13) heart was the only tissue that did not contain detectable amounts of VN (Fig. 1 D). Thus, E13 heart was chosen as the starting tissue for the expression screen. 2 x 106 plaques were screened with the
8ß1-AP, and 18 different phage were recovered. Among these, the cDNA inserts of 15 encoded FN, whereas the other 3 encoded for a novel protein that we have named nephronectin, based on its potential role in kidney development (see below). The longest cDNA of 3.4 kb contains an ORF of 1,683 bp (561 amino acids) (Fig. 2
A). The ORF extends from nucleotide 1241,810 (corresponding to 11,683 of the ORF) of the 3.4-kb cDNA. The first stop codon is followed by several stop codons in multiple reading frames that were confirmed by sequencing a second cDNA. The cDNA contains an AUUAAA motif as a potential polyadenylation signal. This is followed by a GU-rich region
25 nucleotides downstream from the AUUAAA site.
50 nucleotides downstream from the AUUAAA site is another region rich in GU. This pattern of motifs is consistent with the overall structure of described polyadenylation sites (Zhao et al., 1999).
|
Integrin
8ß1 binds to nephronectin in the region containing an RGD sequence in an RGD-dependent manner
Integrin
8ß1 is a member of the RGD-dependent subfamily of integrins (Bossy et al., 1991; Schnapp et al., 1995a,b). To test whether the binding of integrin
8ß1 to nephronectin is RGD sensitive, fragments of nephronectin were expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins (Fig. 3
A). GST-neph251-561 contains the fragment from after EGF repeat 5 to the COOH terminus of the protein (amino acids 251561), GST-neph251-381 from after EGF 5 to immediately before the RGD sequence (amino acids 251381). Both fusion proteins were expressed in E. coli and were purified from the soluble fraction. Some degradation was apparent. Nevertheless, strong binding of
8ß1-AP to GST-neph251-561 was observed (Fig. 3 B).
8ß1-AP binds to the intact fusion protein of
60 kD as well as to two degradation products
50 kD and one
38 kD. This experiment also shows that integrin
8ß1-AP binds to nephronectin in the region COOH-terminal to the EGF repeats. Most likely, the binding site includes the RGD sequence because addition of 50 µg/ml GRGDSP peptide abolished the binding, whereas addition of the same concentration of GRGESP peptide had no effect (Fig. 3 B). To explore this further, GST-neph251-381, a GST fusion protein lacking the RGD and sequences COOH-terminal to the RGD, was used as a substrate and, as expected, did not bind to GST-neph251-381 (Fig. 3 C). Thus, the binding site appears to be contained in amino acids 382561 and is most likely to include the RGD sequence, but this has not been definitely proven by mutation of this sequence.
|
8ß1-AP binds to this fragment of nephronectin under these conditions. A single band of 60 kD is detected. The same band is recognized by antic-myc antibody. Interestingly, the predicted molecular mass for neph251-561 is 41 kD. This suggests the presence of a considerable amount of glycosylation, probably in the mucin-like region of nephronectin.
Characterization of integrin interactions with nephronectin
In an effort to determine whether
8ß1 and additional RGD-binding integrins mediate attachment of cells to nephronectin, we conducted adhesion assays using K562 cells expressing different integrin heterodimers. Parental K562 cells express high levels of
5ß1 and very low or undetectable levels of other integrins (Blystone et al., 1994). Results in Fig. 4
A demonstrate that, even in the presence of Mn2+, which is an activator of all integrins, K562 cells do not bind to the RGD-containing COOH-terminal portion of nephronectin, neph251-561, which was purified from COS-7 cell supernatant. As expected, K562 cells bind efficiently in a dose-dependent manner to FN in the presence of Mn2+, a cation known to activate integrins. In contrast, K562 cells expressing the
8ß1 heterodimer bind efficiently to both FN and nephronectin in dose-dependent manners. Although amounts of the two proteins actually bound to substrata have not be quantitated, the binding curves suggest that
8ß1 binds to lower amounts of nephronectin than FN.
|
8ß1,
Vß3,
Vß5,
Vß6, and
4ß7 bind strongly to this protein in the presence of Mn2+. None of these integrins bound detectably to GST-neph251-381 (not shown), so each could potentially bind to the RGD sequence. In contrast, significant binding was not observed using the parental K562 cells or K562 cells expressing
1ß1,
2ß1,
3ß1, or
4ß1. Each cell line that failed to bind to nephronectin was shown to bind to a characterized ligand for the integrin that it expressed.
1ß1- and
2ß1-expressing cells were shown to adhere efficiently to collagen III.
3ß1-expressing cells adhered efficiently to laminin-5 (kalinin), and
4ß1-expressing cells adhered to FN in the presence of a function-blocking antibody to
5ß1. Thus, nephronectin is a ligand for several activated integrins, including many but not all of the RGD-binding integrins (Yang et al., 1998).
|
8ß1 previously identified in kidney extracts
8ß1, immunodepletions of kidney extracts were performed using an antibody prepared to the recombinant nephronectin fragment GST-neph251-381. The depleted extract and the immunoprecipitate were then analyzed by blotting (Fig. 5) . In comparison to the control, virtually all the 7090-kD ligand(s) for
8ß1 were lost from the depleted extract. In addition, a 7090-kD ligand for
8ß1 was present in the antinephronectin immunoprecipitate. The same doublet of bands was also recognized by the antinephronectin antibody in Western blots of kidney extracts (data not shown). Thus, the 7090-kD
8ß1 ligand(s) in kidney extracts appear to mainly consist of nephronectin.
|
8ß1 interact in the kidney in vivo
8ß1 in blots and cell adhesion assays. To determine whether nephronectin and
8ß1 interact in vivo, we examined whether they could be coimmunoprecipitated from kidney extracts (Fig. 6)
. Extracts were prepared from the kidneys of newborn mice and were immunoprecipitated with antiintegrin
8. The immunoprecipitates were then assayed for the presence of nephronectin using
8ß1-AP (Fig. 6). In the anti-
8 immunoprecipitate,
8ß1-AP detects a doublet of bands identical to those precipitated by antinephronectin. This strongly suggests that integrin
8ß1 and nephronectin are associated with each other in vivo. To test the specificity of this interaction, extracts were prepared from newborn kidneys in the presence of either 10 mM EDTA or GRGDSP peptide to disrupt
8ß1 integrin interactions with its ligands. As a control for the GRGDSP peptide, the experiment was also performed in the presence of GRGESP peptide. The inclusion of either EDTA or GRGDSP, but not GRGESP in the extract and immunoprecipitation buffers greatly reduced the presence of nephronectin in the anti
8 immunoprecipitate. Thus, the integrin
8ß1 and nephronectin are associated in a complex with each other in the developing kidney. This provides strong evidence that nephronectin is an important functional ligand for integrin
8ß1 in the kidney.
|
8ß1-AP, the antinephronectin antibody was first affinity purified on the GST-neph251-561 fusion protein coupled to a Sepharose column and was then passed over a GSTSepharose column to remove antibodies specific for GST (see Materials and methods).
Nephronectin expression can be detected at E10.5 in the urogenital ridge (Fig. 7, A and B)
and at E11.5 in the Wolffian and ureteric bud (Fig. 7 C, inset). At E13.5, nephronectin is localized at the interface between epithelial cells of the ureter and the surrounding metanephric mesenchyme (Fig. 7 C). Nephronectin is also localized between epithelial cells of the ureteric bud and the surrounding mesenchyme. Expression is present at the tips of the ureter branches, but expression levels seem higher around more mature regions of ureteric epithelia (Fig. 7, C and E). In contrast,
8 immunoreactivity is present in the metanephric mesenchyme (Fig. 7, D and F). In addition,
8 also is localized at the interface between the metanephric mesenchyme and the ureteric bud epithelium (Fig. 7 F), as would be anticipated for a receptor to nephronectin.
|
8ß1-AP, and representative results are illustrated in Fig. 7, G and H. In Fig. 7 G, nephronectin is visualized in a branching ureteric bud. The distribution of the ligand detected by
8ß1-AP is illustrated in Fig. 7 H. Comparison of the two panels indicates that the distributions of these two ligands are very similar, compatible with their being the same protein. As kidney development proceeds, the mesenchyme around the tips of the ureteric buds condenses and differentiates into epithelial structures that later fuse with the ureteric buds to form the proximal tubule and glomerulus of the mature kidney. Upon epithelialization of the mesenchyme, very low levels of nephronectin expression become apparent in comma-shaped bodies derived from the mesenchyme (Fig. 7 E). A somewhat later stage of maturation in which the epithelial structure formed by condensing mesenchyme has fused with a ureteric bud is illustrated in Fig. 7 I. Here, expression of nephronectin appears robust in the portion of the tubule derived from the ureteric bud. Expression is low, but significant in the S-shaped body derived from the metanephric mesenchyme. At E18.5, high levels of nephronectin are present in maturing glomeruli (Fig. 7 J).
As described above, the integrin
8ß1 is expressed in the cells of the metanephric mesenchyme. Nephronectin mRNA was detected in RNA blots of kidney throughout metanephric development (not shown). To determine which cells express nephronectin, in situ analyses were performed using antisense and sense cRNA probes. In analyses using the antisense probe, presented in Fig. 8, A, C, and D
, strong expression of mRNA encoding nephronectin is detected in tubular epithelial cells in the E15.5 and P0 kidney. Little or no mRNA is present in the surrounding mesenchyme. Consistent with the localization of nephronectin protein, many condensing mesenchymal structures can be observed that are expressing very low or undetectable levels of nephronectin mRNA. No mRNA is detected at either age using a sense cRNA probe as a control (Fig. 8 B and not shown). A similar but weaker pattern of expression using an antisense probe was observed at E13.5 (not shown). Thus, nephronectin and its receptor
8ß1 appear to be synthesized by complementary cell types during kidney development.
|
| Discussion |
|---|
|
|
|---|
8ß1. We have named this protein nephronectin, because the studies that led to its discovery were initiated in the developing kidney. We have shown that this protein is associated with the extracellular matrix in the kidney where it is synthesized by ureteric epithelial cells and is deposited in the extracellular matrix at the interface between these cells and the metanephric mesenchyme. The integrin
8ß1 is able to bind nephronectin in physiological salt conditions and is associated with nephronectin within the developing kidney in vivo. As an endogenous ligand for this integrin, it seems likely to be important for regulating development of the kidney. As nephronectin is expressed in other tissues and is recognized by other integrins, it may play a wider role in development.
Expression cloning using soluble integrin extracellular domains as probes seems likely to be generally useful for identifying novel ligands for these receptors. This may be particularly relevant since many constituents of the extracellular matrix are not well characterized. For example,
4% of the genes identified in the Drosophila genome sequencing project are candidates for involvement in cell adhesion, and many of these seem likely to be involved in cellular interactions with the extracellular matrix (Hynes and Zhao, 2000). With completion of the C. elegans genome project, it has also become clear that this organism expresses a very large number of extracellular matrixassociated molecules, many of which appear to be species specific (Hutter et al., 2000). It seems almost certain that the completion of vertebrate genome sequencing projects will reveal many additional constituents of the extracellular matrix, many of which are likely to play important roles in organogenesis. The approach described in this paper provides a method for identifying the proteins present in any tissue that mediate cell adhesion. Our methods can also be used to rapidly examine the receptors capable of binding any individual protein. As such, these procedures should be useful in sorting out the functional properties of the diversity of extracellular matrix proteins being identified as part of genomic sequencing projects.
As described in the Results, examination of the EMBL/GenBank/DDBJ database identified a homologue to nephronectin named EGLF6 (human) or MAEG (mouse) (Yeung et al., 1999; Buchner et al., 2000). The sequence of murine nephronectin predicts an ORF of 561 amino acids including a signal sequence of 19 amino acids, whereas that of murine EGFL6/MAEG predicts an ORF of 550 amino acids, including a signal sequence of 18 amino acids. In each protein the signal sequence is followed by five EGF repeats. Interestingly, the sequences of repeats 2, 3, and 4 in EGFL6/MAEG and of repeats 2, 4, and 5 in nephronectin indicate that they are Ca2+-binding EGF domains. This subclass of EGF repeat is found in the extracellular domains of several cell surfaceassociated and extracellular matrix proteins and has been shown to mediate proteinprotein interactions (Rao et al., 1995). Each protein also contains a MAM domain in its COOH-terminal region. MAM domains have also been shown to mediate proteinprotein interactions, so it seems likely that nephronectin and EGFL-6 interact with other proteins or with each other in the extracellular matrix. These are the only genes described to date that contain both Ca2+-binding EGF repeats and MAM domains (Buchner et al., 2000). In the region between the EGF repeats and the MAM domains, both proteins have regions containing an RGD sequence as a potential integrin-binding site and sequences predicted to be modified by N-linked and O-linked glycosylation. Thus, these two proteins share homologies in each of their domains and may form a new subfamily of proteins. Results in this paper have shown directly that nephronectin is localized to the extracellular matrix region in the developing kidney. It seems very likely that EGFL6/MAEG is also a constituent of the extracellular matrix. It will be surprising if it does not prove to be a ligand for some of the RGD-binding integrins.
In previous work, the integrin
8ß1 has been shown to bind many, but not all of the RGD-containing ligands for integrins (Müller et al., 1995; Schnapp et al., 1995b; Varnum-Finney et al., 1995; Denda et al., 1998a,b). These include FN, VN, OPN, and the cell-binding domain of TN-C.
8ß1, however, does not bind detectably to other RGD-containing proteins, such as thrombospondin and entactin (Denda et al., 1998a). Fibronectin has been shown previously to be expressed in the metanephric mesenchyme before invasion by the ureteric bud (Ekblom, 1981; Aufderheide et al., 1987).
8ß1-AP does not exhibit detectable binding to regions of mesenchyme not in contact with the ureteric bud, indicating that it is not binding efficiently to FN (Müller et al., 1997). Even though VN is a well-characterized ligand for this integrin, binding to VN is not observed by
8ß1-AP blots of adult heart, which clearly contains significant amounts of this protein as assessed using anti-VN in Western blots (unpublished data). Thus, the binding of this integrin to VN also appears to be less avid than its binding to nephronectin. Expression of tenascin is restricted to stromal cells in early stages of differentiation (Aufderheide et al., 1987). We have not observed binding to these cells by cytochemistry using
8ß1-AP. After incubations with
8ß1-AP in probes of tissue sections or blots, it is likely that only unusually avid interactions between
8ß1-AP and its ligands are maintained during stringent washes. Consistent with this,
8ß1 and nephronectin remain associated in the presence of detergent in immunoprecipitates of kidney extracts (Fig. 6).
Although RGD peptides have been shown to inhibit binding to other ligands by each of the integrins shown to bind to nephronectin in this paper (Yang et al., 1998), it is less certain that the RGD sequence in nephronectin forms the attachment site for each integrin. In our expression studies, the integrin binding site(s) were mapped roughly to a region of 180 amino acids that includes the RGD site. In particular, the integrin
4 sequence is not in the same subgroup of integrin
sequences as those of
V-,
5-, and
8-, and
4-containing integrins have been shown to bind to sequences not containing an RGD site (Moyano et al., 1997).
As described above, the distribution of nephronectin in the developing kidney appears to be essentially identical to that of the ligand(s) detected by
8ß1-AP, and nephronectin is clearly the major protein detected in blots of embryonic kidney extracts using
8ß1-AP. It is unusual for an integrin to remain associated with its ligands after immunoprecipitation, so the association of nephronectin with
8ß1 in immunoprecipitates suggests that these two proteins are associated in vivo. For this reason, it seems very likely to be a critical ligand in the signaling pathway in early metanephric kidney development that was revealed by the phenotype of mice lacking
8ß1. Although this ligand is very likely to be functionally important, we can not exclude roles for other matrix proteins. As summarized in the Introduction, with the exception of OPN, none of the other known ligands for
8ß1 has a distribution appropriate to mediate the essential interactions with
8ß1 revealed by the
8 mutant. OPN has been shown to be a ligand for
8ß1 (Denda et al., 1998b). OPN has also been shown to be localized in the extracellular matrix between the ureteric bud epithelium and metanephric mesenchyme in approximately the same distribution as the ligand detected by
8ß1-AP and antibodies to OPN inhibit development of organ-cultured embryonic kidneys (Rogers et al., 1997). Notably, though, mice lacking OPN develop normal kidneys (Liaw et al., 1998), and we have shown that these mice continue to express a ligand in the extracellular matrix between the ureteric bud epithelium and metanephric mesenchyme that is detected by
8ß1-AP (data not presented). These data leave open the possibility that OPN and nephronectin have overlapping roles in kidney development. mRNA encoding EGFL6/MAEG is also present in the embryonic kidney (Buchner et al., 2000), so this protein may also help regulate kidney development.
The identification and characterization of nephronectin should be useful in pursuing studies on the puzzling phenotype of the
8 mutant. As summarized in the Introduction, the earliest phenotype observed in the
8 mutant is a delay in growth of the ureteric bud into the metanephric mesenchyme (Müller et al., 1997). Since the integrin
8ß1 is expressed in the mesenchyme and not in the ureteric bud epithelium, this observation suggests that the integrin functions in the mesenchyme to control expression or signaling efficiency of a factor necessary for ureteric bud growth. During the past few years, analyses of several mutants have identified a growth factormediated signaling pathway important in this process. Glial cellderived neurotrophic factor (GDNF) is synthesized in the metanephric mesenchyme (Moore et al., 1996). Secreted GDNF has been shown to control ingrowth of the ureteric bud by binding to GFR-
1, which results in activation of the c-ret tyrosine kinase (for review see Sariola and Sainio, 1997). The early phenotypes of mice lacking GDNF, GFR-
1, or c-ret are very similar to that of mice lacking the
8ß1 integrin, so it seems likely that this integrin is involved in this signaling pathway. Potentially, nephronectin acting through
8ß1 could induce a signaling pathway that results in enhanced expression of GDNF. Alternatively, it could synergize with GDNF by promoting secretion of this factor or its localization in the extracellular matrix. Whatever the mechanism, further investigations using this ligand should advance our understanding of the puzzling function of
8ß1 in kidney development.
| Materials and methods |
|---|
|
|
|---|
8ß1-AP as follows. Lambda phage was plated onto 15-cm NZY plates with host bacteria at a density of 50,000 plaque forming units, as recommended by the manufacturer. Plates were incubated for 3 h at 42°C until plaques were just visible. Nitrocellulose membranes (Stratagene) were wetted in 10 mM isopropyl-ß-D-galactopyranoside and air dried. The membranes were placed on the plates and incubated overnight at 30°C. Membranes were removed, washed several times with TBS (20 mM Tris/HCl, pH 7.5, 150 mM NaCl), blocked with TBS containing 3% milk powder, probed with
8ß1-AP, and developed as described above with the addition of MnCl2. Phage were recovered from positive plaques and rescreened until a single plaque could be picked. Excision of phage and plasmid recovery were done as described in the Stratagene manual.
Recombinant protein production
The nephronectin fragments neph251-561 (amino acids 251561) and neph251-381 (amino acids 251381) were expressed as NH2-terminal GST fusion proteins in E. coli. Both fragments were generated by PCR and cloned into the pGEX-4T-3 vector (Amersham Pharmacia Biotech). Constructs were verified by sequencing. Recombinant fusion proteins were expressed in E. coli BL21 cells. Bacteria were grown at 37°C in LB medium to OD600 = 0.8 and were then transferred to 30°C. Cells were induced with 1 mM isopropyl-ß-D-thiogalactopyranoside and grown for an additional 2.5 h. Cells were collected by centrifugation, resuspended in lysis buffer (50 mM Tris-Cl, pH 8, 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100 containing 1 µg/ml PMSF, 2 µg/ml aprotinin, 0.7 µg/ml pepstatin A), and lysed by sonication. After centrifugation, the supernatant was incubated for 1 h at 4°C with glutathioneSepharose (Amersham Pharmacia Biotech). Beads were washed with lysis buffer and with PBS and eluted with PBS containing 50 mM reduced glutathione.
For expression of the nephronectin fragment neph251-561 (amino acids 251561) in COS7 cells, a PCR fragment was generated and cloned into the pSecTag2 vector (Invitrogen) containing an Ig
chain signal peptide and a COOH-terminal myc/His6 tag. COS7 cells were grown in DME (GIBCO BRL) supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were transiently transfected with LipofectAmine (GIBCO BRL). After transfection, medium was changed to DME supplemented with Nutridoma HU (Roche Biochemicals) and penicillin/streptomycin. Conditioned medium was collected every 2 d for 8 d.
To establish stably transfected cell lines, CHO cells were transfected with the pSecTag2-neph251-561 vector described above. 24 h after transfection, 500 micrograms/ml zeocin (Invitrogen) was added to the medium. After 23 wk selection, single colonies were picked and expanded. Expanded clones were screened by Western blot for expression of neph251-561. For expression of recombinant neph251-561, stably transfected CHO cells were adapted to serum-free CHO-S-SFMII medium (GIBCO BRL) according to the manufacturer's instructions and grown in spinner bottles in the presence of 250 µg/ml zeocin. Conditioned medium was harvested when cell density was >12 10 x 6 cells/ml. Cells and debris were removed by centrifugation. After the addition of 0.02% sodium azide and 1 µ/ml PMSF, the medium was filtered (number 1 filter; Whatman) and concentrated 1020-fold using a S1Y30 spiral ultrafiltration cartridge (Amicon), followed by a second 10-fold concentration step through a 10-kD cut-off ultrafiltration membrane (Amicon).
As a preclearing step, the supernatant was passed twice over a protein GSepharose column (Amersham Pharmacia Biotech). The flow-through was adsorbed to a protein GSepharose column coupled with antic-myc antibody 9E10 (Developmental Studies Hybridoma Bank). The column was washed with 10-column volumes PBS and eluted with 100 mM triethylamine, pH 11, washed with PBS, and eluted again with 100 mM glycine, pH 2.5. Fractions from both elution steps containing purified nephronectin were identified by blotting with
8ß1-AP and were dialyzed against PBS. Protein was quantified by standard protein assay (Bio-Rad Laboratories).
Recombinant
8ß1-AP was expressed as described (Denda et al., 1998a). Conditioned medium was concentrated 100-fold. Then, Tris-Cl, pH 8, was added to a final concentration of 20 mM, and PMSF was added to 1 µg/ml. For use on blots, the conditioned medium was diluted 510-fold with blocking buffer (see below).
Antibodies and reagents
An antiserum to nephronectin was generated by immunizing rabbits with purified GST fusion protein, GST-neph251-381. For immunohistochemistry, the antibody was affinity purified against GST-neph251-381 coupled to CNBr-Sepharose (Amersham Pharmacia Biotech). The antiserum was passed over a Sepharose column coupled to GST to remove antibodies recognizing the GST. Specificity of the affinity-purified antibody was tested by Western blot with a maltose-binding proteinnephronectin fusion protein.
Antiserum 1526 against the integrin
8 extracellular domain used in this study has been described previously (Müller et al., 1997). Antimouse VN was a gift from D. Seiffert (Seiffert, 1996). Antic-myc 9E10 ascites was generated using the hybridoma cell line 9E10 developed by J.M. Bishop and was obtained from the Developmental Studied Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. Human plasma FN, the 120-kD FN fragment (FN120), bovine plasma VN, and GRGDSP and GRGESP peptides were purchased from GIBCO BRL.
Protein extracts
Newborn mouse kidneys were homogenized in ice-cold TBS containing 1 mM PMSF, 10 µg/ml leupeptin, and 0.7 µg/ml pepstatin A at a 10:1 vol/wt ratio. After centrifugation at 15,000 g in a tabletop centrifuge for 30 min, the pellet was resuspended in extraction buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 50 mM n-octylglucoside, 2 mM MgCl2, 1 µg/ml PMSF, 10 µg/ml leupeptin, 0.7 µg/ml pepstatin A). After a 10-min extraction, samples were centrifuged at 15,000 rpm for 30 min to remove debris. Protein concentrations were determined with the detergent compatible protein assay (Bio-Rad Laboratories), and 100 µg total protein was loaded on SDS-PAGE.
Protein blots
For antigen and
8ß1-AP ligand blotting, protein extracts or purified proteins were boiled in SDS sample buffer, separated on 7 or 12% SDS-PAGE and transferred to nitrocellulose membranes. Nonspecific binding sites were blocked with blocking buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 3% milk powder) at room temperature. For Western blots, the nitrocellulose was incubated with antibodies diluted in blocking buffer for 1 h at room temperature, washed three times for 5 min each with wash buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), and incubated with secondary antibody (goat antirabbit IgG, AP conjugated; Sigma-Aldrich) for 1 h at room temperature. This was followed by three washes of 5 min each with wash buffer and two washes with a AP buffer (100 mM Tris-Cl, pH 9.5, 100 mM NaCl, 5 mM MgCl2). Nitrocellulose membranes were then developed with AP buffer containing 0.33 mg/ml NBT and 0.17 mg/ml BCIP. For blotting using
8ß1-AP, blocked nitrocellulose membranes were incubated with
8ß1-AP in blocking buffer containing 2 mM MgCl2 or MnCl2 for 2 h at room temperature. Membranes were washed three times for 5 min with TBS containing 2 mM MgCl2 or MnCl2, followed by two washes with AP buffer. For incubations with MnCl2, 0.5 mM MnCl2 was included in the AP buffer. Blots were developed with AP buffer containing 0.33 mg/ml nitro blue tetrazolium and 0.17 mg/ml 5-bromo-4-chloro-3-indolylphosphate.
Immunohistochemistry
Histological methods were carried out as described previously (Jones et al., 1994). Immunohistochemistry with antiintegrin
8 antiserum 1526 and with
8ß1-AP have been described previously (Müller et al., 1997; Denda et al., 1998b). For staining with antinephronectin antibodies, sections were blocked with 1% BSA, 0.1% Triton X-100, 1% H2O2 in PBS; washed with 1% BSA, 0.1% Triton X-100 in PBS; incubated with affinity-purified antinephronectin antibody at 10 µg/ml in the same buffer; washed and detected with the ABC kit (Vector Laboratories); and counterstained with Nissl as described (Jones et al., 1994).
In situ hybridization
In situ hybridization was carried out on fresh frozen sections as described (Schaeren-Wiemers and Gerfin-Moser, 1993). For digoxygenin labeling of probes and detection of signal, the digoxygenin RNA labeling and detection kit (Roche Biochemicals) was used. A 0.9-kb nephronectin cDNA fragment was used as template.
Immunoprecipitation
For immunoprecipitation, antiintegrin
8 antibody was covalently coupled to protein ASepharose, that was added to 500 µl kidney extract for 2 h at 4°C. The beads were washed three times for 5 min with wash buffer (50 mM Tris-Cl, pH 7.5, 500 mM NaCl, 50 mM n-octylglucoside, 2 mM MgCl2, 1 µg/ml PMSF, 10 µg/ml leupeptin, 0.7 µg/ml pepstatin A). After addition of SDS sample buffer, the beads were boiled for 5 min and centrifuged. The supernatant was collected for blot analysis.
Coimmunoprecipitations
For coimmunoprecipitations, extracts and immunoprecipitations were done as above. As controls, 10 mM EDTA instead of MgCl2 or 600 µg/ml GRGDSP and GRGESP peptides were added to all the extraction buffers and wash buffers in the control samples.
Cell adhesion assays
For cell adhesion assays, substrate protein was diluted in PBS to the indicated concentrations. Linbro Titertek 96-well plates (Flow Laboratories) were then treated overnight at 4°C with a total volume of 100 µl of substrate solution per well. The wells were blocked with 10 mg/ml BSA in PBS for 1 h at 37°C. The cells were harvested with PBS containing 1 mM EDTA, washed once in TBS (24 mM Tris-Cl, pH 7.4, 137 mM NaCl, 2.7 mM KCl), counted, and then resuspended in TBS containing 0.1% BSA, 2 mM glucose, 1 mM MnCl2. The cells were counted once again, and a total of 2.0 x 105 cells were plated per well. The cells were incubated for 1.5 h at 37°C, washed four times with TBS containing 1 mM MnCl2, fixed for 15 min with 2% paraformaldehyde, and stained for 5 min with 2.5% crystal violet in 20% ethanol. Finally, each well was washed four times with water, and adherent cells were lysed with 1% SDS. Absorption values for each well were read at 570 nm using a microtiter plate reader and SOFTmax v2.35 (Molecular Devices). Final absorption values for wells coated with FN or nephronectin GST fusion proteins were determined by calculating the mean absorption value of duplicate or quadruplicate wells and subtracting the mean value from either BSA- or GST-treated control wells run in parallel. For antibody inhibition, cells were preincubated for 15 min on ice with the antibody before plating. Antibody was present throughout the adhesion assay. Antibody BIIG2 (anti-
5) was supplied as an ascites. This ascites blocked adhesion of the parental K562 cells to FN at a dilution of 1:20. K562 adhesion to FN was not affected by a control ascites when used at the same concentration.
| Footnotes |
|---|
Sumiko Denda's present address is Shisheido Research Center 2, 2-12-1 Fukuura, Kanazawa-ku, Yokohama 236-8643, Japan.
Ullrich Müller's present address is Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058 Basel, Switzerland.
* Abbreviations used in this paper: AP, alkaline phosphatase; FN, fibronectin; GDNF, glial cellderived neurotrophic factor; GST, glutathione S-transferase; OPN, osteopontin; TN-C, tenascin-c; VN, vitronectin.
| Acknowledgments |
|---|
Vß3,
Vß5,
Vß6,
4ß1, and
4ß7; and Dr. Martin Hemler (Dana Farber Cancer Institute, Boston, MA) for providing K562 cells expressing
2ß1 and
3ß1. We thank Dr. Caroline Damsky (University of California, San Francisco) for anti-
5ß1 mAb. This work was supported by the Howard Hughes Medical Institute. R. Brandenberger was supported by fellowships from the Swiss National Science Foundation and the Human Frontiers Science Program. L.F. Reichardt is an investigator of the Howard Hughes Medical Institute.
Note added in proof: Since submision of this manuscript, Dr. Kenichi Tezuka and colleagues (Science University of Tokyo, Yamazaki, Noda, Chiba, Japan) have informed us that KA8 cells (the K562 cells expressing the integrin
8ß1, used in our paper) bind to a novel protein named POEM (preosteoblast EGF-like repeat protein with MAM domain). Dr. Tezuka and colleagues sent us the sequence of the first 15 amino acids of POEM, and this sequence is identical to that of the corresponding residues in nephronectin. Also, POEM has the same number of EGF repeats and the same overall structure as nephronectin. Nephronectin and POEM thus are almost certainly the same protein. Dr. Tezuka and colleagues have submitted a manuscript on their work.
Submitted: 15 March 2001
Revised: 22 May 2001
Accepted: 23 May 2001
| References |
|---|
|
|
|---|
Aufderheide, E., R. Chiquet-Ehrismann, and P. Ekblom. 1987. Epithelialmesenchymal interactions in the developing kidney lead to expression of tenascin in the mesenchyme. J. Cell Biol. 105:599608.
Blystone, S.D., I.L. Graham, F.P. Lindberg, and E.J. Brown. 1994. Integrin
Vß3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor
5ß1. J Cell Biol. 127:11291137.
Bossy, B., E. Bossy-Wetzel, and L.F. Reichardt. 1991. Characterization of the integrin
8 subunit: a new integrin ß1 associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos. EMBO J. 10:23752385.
Buchner G, U. Orfanelli, N. Quaderi, M.T. Bassi, G. Andolfi, A. Ballabio, and B. Franco. 2000. Identification of a new EGF-repeat-containing gene from human Xp22: a candidate for developmental disorders. Genomics. 65:1623.
Denda, S., U. Müller, K.L. Crossin, H.P. Erickson, and L.F. Reichardt. 1998a. Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin
8ß1 receptor interactions with tenascin: murine
8ß1 binds to the RGD site in tenascin-c fragments, but not to native tenascin-c. Biochemistry. 37:54645474.
Denda, S., L.F. Reichardt, and U. Müller. 1998b. Identification of osteopontin as a novel ligand for the integrin
8ß1 and potential roles for this integrin-ligend interaction in kidney morphogenesis. Mol. Biol. Cell. 9:14251435.
Ekblom, P. 1981. Formation of basement membranes in the embryonic kidney: an immunohistochemical study. J. Cell Biol. 91:110.
Fässler, R., E. Georges-Labouesse, and E. Hirsch. 1996. Genetic analysis of integrin function in mice. Curr. Opin. Cell Biol. 8:641646.
George, E.L., E.N. Georges-Labouesse, R.S. Patel-King, H. Rayburn, and R.O. Hynes. 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 119:10791091.
Hansen, J.E., O. Lund, N. Tolstrup, A.A. Gooley, K.L. Williams, and S. Brunak. 1998. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconjugate J. 15:115130.
Hutter, H., B.E. Vogel, J.D. Plenefisch, C.R. Norris, R.B. Proenca, J. Spieth, C. Guo, S. Mastwal, X. Shu, J. Scheel, and E.M. Hedgecock. 2000. Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes. Science. 287: 989994.
Hynes, R.O. 1996. Targeted mutations in cell adhesion genes: what have we learned from them? Dev. Biol. 180:402412.
Hynes, R.O., and Q. Zhao. 2000. The evolution of cell adhesion. J. Cell Biol. 150:F89F95.
Jones, K.R, I. Fariñas, C. Backus, and L.F. Reichardt. 1994. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell. 76:989999.
Lan. M.S., S.K. Batra, W.N. Qi, R.S. Metzgar, and M.A. Hollingsworth. 1990. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265:1529415299.
Liaw, L., D.E. Birk, C.B. Ballas, J.S. Whitsitt, J.M. Davidson, and B.L. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (ssp1). J. Clin. Invest. 101:14681478.
Moore, M.W., R.D. Klein, I. Farinás, H. Eauer, M. Aronanini, H. Phillips, L.F. Reichardt, A.M. Ryan, K.C. Carver-Moore, and A. Rosenthal. 1996. Absence of kidneys and enteric nervous system but not of CNS dopaminergic or noradrenergic neurons in glial-derived neurotrophic factor deficient mice. Nature. 382:7679.
Moyano, J.V., B. Carnemolla, C. Dominguez-Jimenez, M. Garcia-Gila, J.P. Albar, P. Sanchez-Aparicio, A. Leprini, G. Querze, L. Zardi, and A. Garcia-Pardo. 1997. Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated
4ß1 and
4ß7 integrins. J. Biol. Chem. 272:2483224836.
Müller, U., B. Bossy, K. Venstrom, and L.F. Reichardt. 1995. Integrin
8ß1 promotes attachment, cell spreading, and neurite outgrowth on fibronectin. Mol. Biol. Cell. 6:433448.
Müller, U., D. Wang, S. Denda, J.J. Meneses, R.A. Pedersen, and L.F. Reichardt. 1997. Integrin
8ß1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell. 88:603613.
Rao, Z., P. Handford, M. Mayhew, V. Knott, G.G. Brownlee, and D. Stuart. 1995. The structure of a Ca2+-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell. 82:131141.
Rogers, S. A., B.J. Padanilam, K.A. Hruska, C.M. Giachelli, and M.R. Hammerman. 1997. Metanephric osteopontin regulates nephrogenesis in vitro. Am. J. Physiol. 272:F469F476.
Saga, Y., T. Yagi, Y. Ikawa, T. Sakakura, and S. Aizawa. 1992. Mice develop normally without tenascin. Genes Dev. 6:18211831.
Sariola, H., and K. Sainio. 1997. The tip-top branching ureter. Curr. Opin. Cell Biol. 9:877884.
Schaeren-Wiemers, N., and A. Gerfin-Moser. 1993. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes. Histochemistry. 100:431440.
Schnapp, L.M., J.M. Breuss, D.M. Ramos, D. Sheppard, and R. Pytela. 1995a. Sequence and tissue distribution of the human integrin
8 subunit: a ß1-associated
subunit expressed in smooth muscle cells. J. Cell. Sci. 108:537544.
Schnapp, L.M., N. Hatch, D.M. Ramos, I.V. Klimanskaya, D. Sheppard, and R. Pytela. 1995b. The human integrin
8ß1 functions as a receptor for tenascin, fibronectin, and vitronectin. J. Biol. Chem. 270:2319623202.
Seiffert, D. 1996. Detection of vitronectin in mineralized bone matrix. J. Histochem. Cytochem. 44:275280.
Seiffert, D., M. Keaton, T. Eguchi, M. Sawday, and D.J. Loskutoff. 1991. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc. Natl. Acad. Sci. USA. 88:94029406.
Varnum-Finney, B., K. Venstrom, U. Müller, R. Kypta, C. Backus, M. Chiquet, and L.F. Reichardt. 1995. The integrin receptor
8ß1 mediates interactions of embryonic chick motor and sensory neurons with tenascin-C. Neuron. 14:12131222.
Yeung, G., J.J. Mulero, R.P. Berntsen, D.B. Loeb, R. Drmanac, and J.E. Ford. 1999. Cloning of a novel epidermal growth factor repeat containing gene EGFL6: expressed in tumor and fetal tissues. Genomics. 62:304307.
Yang, Y., P.M. Cardarelli, K. Lehnert, S. Rowland, and G.W. Krissansen,. 1998. LPAM-1 (integrin
4ß7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur. J. Immunol. 28:9951004.
Zhao, J., L. Hyman, and C. Moore. 1999. Formation of mRNA 3' ends in eukaryotes: mechanisms, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol. Mol. Biol. Rev. 63:405445.
Zheng, X., T.L. Saunders, S.A. Camper, L.C. Samuelson, and D. Ginsburg. 1995. Vitronectin is not essential for normal mammalian development and fertility. Proc. Natl. Acad. Sci. USA. 92:1242612430.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|